Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel ginsenoside liposome injection
- Development stage
- Preclinical
- Lead developer
- Hangzhou Jinshennuo Biopharmaceutical
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Cabazitaxel ginsenoside liposome injection (Ginposome-CTX) is an innovative liposomal formulation of the taxane chemotherapy agent cabazitaxel, developed by Xiamen Ginposome Pharmaceutical. The drug utilizes a proprietary ginsenoside-based liposome delivery system (Ginposome DDS), where ginsenosides (specifically ginsenoside Rg3) replace cholesterol as the membrane-stabilizing material. This approach is designed to improve the pharmacokinetic profile of cabazitaxel and potentially enhance therapeutic efficacy through the intrinsic anti-tumor properties of ginsenosides. Cabazitaxel functions by binding to and stabilizing tubulin within microtubules, preventing their disassembly and leading to cell cycle arrest and apoptosis. The product is administered intravenously and is currently in the NDA filing stage in China for the treatment of prostate cancer.
- Other names
- 注射用复方卡巴他赛人参皂苷脂质体Cabazitaxel + liposomal ginsenoside
02
Targets
SLC2A4 (Solute carrier family 2 facilitated glucose transporter member 4)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel ginsenoside liposome injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel ginsenoside liposome injection.